Global MRD (Minimal Residual Disease) Testing Market Insights, Forecast to 2028

Minimal residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment. The number of remaining cells may be so small that they do not cause any physical signs or symptoms and often cannot even be detected through traditional methods, such as viewing cells under a microscope and/or by tracking abnormal serum proteins in the blood. An MRD positive test result means that residual (remaining) disease was detected. A negative result means that residual disease was not detected,The most widely used tests to measure MRD are flow cytometry, polymerase chain reaction (PCR) and next-generation sequencing (NGS).
Market Analysis and Insights: Global MRD (Minimal Residual Disease) Testing Market
Due to the COVID-19 pandemic, the global MRD (Minimal Residual Disease) Testing market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Flow Cytometry accounting for % of the MRD (Minimal Residual Disease) Testing global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Specialty Clinics and Hospitals segment is altered to an % CAGR throughout this forecast period.
China MRD (Minimal Residual Disease) Testing market size is valued at US$ million in 2021, while the US and Europe MRD (Minimal Residual Disease) Testing are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe MRD (Minimal Residual Disease) Testing landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of MRD (Minimal Residual Disease) Testing include ICON plc, ArcherDX(Invitae), ARUP Laboratories, Asuragen, Cergentis B.V., Bio-Rad Laboratories, Mission Bio, Guardant Health and Invivoscribe, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global MRD (Minimal Residual Disease) Testing Scope and Segment
MRD (Minimal Residual Disease) Testing market is segmented by Type and by Application. Players, stakeholders, and other participants in the global MRD (Minimal Residual Disease) Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Segment by Application
Specialty Clinics and Hospitals
Diagnostic Laboratories
Research Institutions
By Company
ICON plc
ArcherDX(Invitae)
ARUP Laboratories
Asuragen
Cergentis B.V.
Bio-Rad Laboratories
Mission Bio
Guardant Health
Invivoscribe
LabCorp
Inivata
Natera
NeoGenomics Laboratories
Opko Health
Quest Diagnostics
Sysmex Corporation
Adaptive Biotechnologies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE